

1 **Title Page**

2

3 **Article Type:** Research Article

4

5 **Title:** Potential impact of outpatient stewardship interventions on antibiotic exposures of  
6 bacterial pathogens

7

8 **Authors:** Christine Tedijanto,<sup>1</sup> Yonatan H Grad,<sup>2,3</sup> Marc Lipsitch<sup>1,2</sup>

9

10 **Author Affiliations:** <sup>1</sup> Center for Communicable Disease Dynamics, Department of  
11 Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA;  
12 <sup>2</sup> Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public  
13 Health, Boston, Massachusetts, USA; <sup>3</sup> Division of Infectious Diseases, Brigham and Women's  
14 Hospital, Harvard Medical School, Boston, Massachusetts, USA

15

16 **Corresponding Author:** Christine Tedijanto, [ctedijanto@g.harvard.edu](mailto:ctedijanto@g.harvard.edu)

17

18 **Manuscript Word Count:** 4,632

19

20 **Abstract**

21 The relationship between antibiotic stewardship and population levels of antibiotic resistance  
22 remains unclear. In order to better understand shifts in selective pressure due to stewardship, we  
23 use publicly available data to estimate the effect of changes in prescribing on exposures to  
24 frequently used antibiotics experienced by potentially pathogenic bacteria that are  
25 asymptotically colonizing the microbiome. We quantify this impact under four hypothetical  
26 stewardship strategies. In one scenario, we estimate that elimination of all unnecessary outpatient  
27 antibiotic use could avert 6 to 48% (IQR: 17 to 31%) of exposures across pairwise combinations  
28 of sixteen common antibiotics and nine bacterial pathogens. All scenarios demonstrate that  
29 stewardship interventions, facilitated by changes in clinician behavior and improved diagnostics,  
30 have the opportunity to broadly reduce antibiotic exposures across a range of potential  
31 pathogens. Concurrent approaches, such as vaccines aiming to reduce infection incidence, are  
32 needed to further decrease exposures occurring in “necessary” contexts.

### 33 **Introduction**

34 Antibiotic consumption is a known driver of antibiotic resistance. In developed nations, over  
35 80% of antibiotic consumption for human health occurs in the outpatient setting (European  
36 Centre for Disease Prevention and Control, 2018; Public Health Agency of Canada, 2018; Public  
37 Health England, 2017; Swedres-Svarm, 2017), and US-based studies conducted across different  
38 subpopulations have estimated that 23-40% of outpatient prescriptions may be inappropriate  
39 (Chua, Fischer, & Linder, 2019; Fleming-Dutra et al., 2016; Olesen, Barnett, MacFadden,  
40 Lipsitch, & Grad, 2018). Inappropriate antibiotic use leads to increased risk of adverse events  
41 (Linder, 2008; Shehab, Patel, Srinivasan, & Budnitz, 2008), disruption of colonization resistance  
42 and other benefits of the microbial flora (Buffie & Pamer, 2013; Khosravi & Mazmanian, 2013),  
43 and bystander selection for antibiotic resistance, with little to no health gains for the patient.  
44 Recent work on bystander selection estimates that, for 8 of 9 potential pathogens of interest, over  
45 80% of their exposures to commonly used antibiotic classes in the outpatient setting occur when  
46 the organisms are asymptotically colonizing the microbiome, not causing disease (Tedijanto,  
47 Olesen, Grad, & Lipsitch, 2018). A corollary of extensive bystander selection is that reductions  
48 in use will prevent antibiotic exposures for species throughout the microbiome.

49  
50 We use publicly available data to quantify potentially avertable exposures of bacterial species to  
51 commonly used antibiotics under hypothetical changes in prescribing practice. The set of  
52 scenarios included here are intended as thought experiments to explore the upper bounds of  
53 avertable antibiotic exposures. Reductions in antibiotic consumption have historically had  
54 variable impacts on resistance levels, likely dependent on setting, baseline consumption and  
55 resistance patterns, and fitness costs (Andersson & Hughes, 2010; Lipsitch, 2001). In addition,

56 treatment strategies are primarily guided by randomized controlled trials assessing immediate  
57 clinical outcomes, with less careful consideration given to the microbiome-wide effect of such  
58 decisions. We apply analytical methods to parse out species-level effects of changes in  
59 prescribing practice in order to better understand the potential impact of antibiotic stewardship.

60

## 61 **Methods**

### 62 *Scenarios of interest*

63 This analysis includes sixteen antibiotics that are frequently prescribed in the outpatient setting  
64 and nine potentially pathogenic bacterial species that are commonly carried in the normal human  
65 microbiome. For each antibiotic-species pair, we estimate the proportion of antibiotic exposures  
66 experienced by that species that could be averted under four hypothetical scenarios. The  
67 scenarios range from broad elimination of unnecessary prescribing to focused modifications of  
68 antibiotic use for specific indications as follows:

- 69 1) Eliminate unnecessary antibiotic use across all outpatient conditions.
- 70 2) Eliminate all antibiotic use for outpatient respiratory conditions for which antibiotics are  
71 not indicated.
- 72 3) Eliminate all antibiotic use for acute sinusitis.
- 73 4) Prescribe nitrofurantoin for all cases of cystitis in women.

74 We use the results reported by Fleming-Dutra and colleagues as estimates of unnecessary  
75 antibiotic use in ambulatory care settings (Fleming-Dutra et al., 2016). In this study, the authors  
76 convened a group of experts to estimate the proportion of appropriate antibiotic use by condition  
77 and age group based on clinical guidelines. When guidelines could not be used for this task, the  
78 rate of appropriate antibiotic prescribing was estimated by benchmarking against the lowest-



79 prescribing US region. Based on the same paper, we consider viral upper respiratory tract  
80 infection, influenza, non-suppurative otitis media, viral pneumonia, bronchitis, and allergy and  
81 asthma to be outpatient respiratory conditions for which antibiotics are not indicated.  
82  
83 Antibiotic treatment of acute bacterial sinusitis is currently guideline-recommended (Rosenfeld  
84 et al., 2015). However, bacteria are an infrequent cause of acute sinusitis, and due to the self-  
85 limiting nature of the syndrome, evidence to support antibiotic treatment is weak (Burgstaller,  
86 Steurer, Holzmann, Geiges, & Soyka, 2016; Fokkens, Lund, & Mullol, 2007). The cause of  
87 sinusitis (whether bacterial, viral, or noninfectious) can be very difficult to distinguish in  
88 practice, and as a result of this challenge and others, antibiotics continue to be prescribed at over  
89 80% of US outpatient visits with a primary diagnosis of acute sinusitis (Smith et al., 2013). In  
90 contrast, antibiotics are always recommended for urinary tract infections (UTIs). Despite being  
91 recommended as a second-line therapy for cystitis due to concerns about resistance,  
92 fluoroquinolones are the most common treatment, prescribed at 40% of outpatient visits for  
93 uncomplicated UTI (Kabbani et al., 2018). We explore the hypothetical scenario of treating all  
94 cases of cystitis in women with nitrofurantoin, a recommended first-line therapy with good  
95 potency against common uropathogens, low levels of resistance, and decreased risk of collateral  
96 damage to the intestinal microbiome due to its propensity to concentrate in the bladder (Gupta et  
97 al., 2011; Gupta, Scholes, & Stamm, 1999; Stewardson et al., 2015). Nitrofurantoin is considered  
98 clinically appropriate unless the patient has chronic kidney disease, is showing signs of early  
99 pyelonephritis, or has had a prior urinary isolate resistant to nitrofurantoin (Hooton & Gupta,  
100 2019). In our analysis, we exclude patients with a simultaneous diagnosis of pyelonephritis. We  
101 assume that other contraindications are fairly rare in the general population.

102 *Data sources and methodology*

103 Extending our recent work on bystander selection (Tedijanto et al., 2018), we used the 2015  
104 National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care  
105 Survey (NAMCS/NHAMCS) (National Center for Health Statistics, 2015a, 2015b), the Human  
106 Microbiome Project (HMP) (Huttenhower et al., 2012; The Human Microbiome Project  
107 Consortium, 2012), and assorted carriage and etiology studies (Bäckhed et al., 2015; Bluestone,  
108 Stephenson, & Martin, 1992; Bogaert et al., 2011; Brook, Thompson, & Frazier, 1994; Celin,  
109 Bluestone, Stephenson, Yilmaz, & Collins, 1991; Chira & Miller, 2010; Edlin, Shapiro, Hersh, &  
110 Copp, 2013; Ginsburg et al., 1985; Gunnarsson, Holm, & Söderström, 1997; Gupta et al., 1999;  
111 Jack M. Gwaltney, Scheld, Sande, & Sydnor, 1992; Hammitt et al., 2006; Holgerson, Öhman,  
112 Rönnlund, & Johansson, 2015; Susan S. Huang et al., 2009; Jain et al., 2015; Arch G. Mainous,  
113 Hueston, Everett, & Diaz, 2006; Pettigrew et al., 2012; Regev-Yochay et al., 2004; Verhaegh et  
114 al., 2010; Loretta Wubbel et al., 1999; Yassour et al., 2016) (details in Figure 1 – Source Data  
115 File 1) to estimate national outpatient antibiotic exposures by drug, species, and condition.  
116 NAMCS/NHAMCS are annual cross-sectional surveys designed to sample outpatient visits in  
117 the United States, and up to five diagnoses and thirty medications may be associated with each  
118 visit. We used methodology developed by Fleming-Dutra and colleagues (Fleming-Dutra et al.,  
119 2016), and applied in other studies (Olesen, Barnett, MacFadden, Lipsitch, et al., 2018), to group  
120 diagnosis codes into conditions and link antibiotic prescriptions with the most likely indication.  
121 For this analysis, visits with a diagnosis of acute cystitis (ICD-9-CM: 595.0), unspecified cystitis  
122 (595.9) or unspecified UTI (599.0), without a concurrent diagnosis of pyelonephritis (590.1,  
123 590.8), renal abscess (590.2), or kidney infection (590.9), were considered to be associated with  
124 cystitis. In this analysis, we maintain the assumption that one antibiotic prescription is equivalent

125 to one exposure; antibiotic exposures experienced by a given species and associated with a given  
126 condition are roughly estimated as the product of antibiotic prescriptions for that condition and  
127 species carriage prevalence, which is dependent on disease etiology (target exposures) and  
128 asymptomatic carriage prevalence (bystander exposures). For diagnoses where etiology was not  
129 readily available, we assumed that none of our species of interest were causative agents. These  
130 assumptions have been enumerated in detail in prior work (Tedijanto et al., 2018). We applied  
131 proportions of unnecessary antibiotic prescribing by condition and age group estimated by  
132 Fleming-Dutra and colleagues based on expert opinion, clinical guidelines, and regional  
133 variability in use (Fleming-Dutra et al., 2016). For relevant scenarios (1 and 2), we applied the  
134 proportions of unnecessary use evenly across all antibiotic prescriptions. Antibiotics and  
135 antibiotic classes are identified by the Lexicon Plus® classification scheme (*Lexicon Plus*,  
136 2008).

137  
138 The proportion of avertable antibiotic exposures for each species is defined by Equation 1. The  
139 equation adopts previously described notation (Tedijanto et al., 2018) with modifications. A  
140 listing of all variables and descriptions can be found in Equation 1 – Figure Supplement 1. Let  $a$   
141 represent antibiotic,  $s$  represent species,  $i$  represent ICD-9-CM diagnosis code, and  $g$  represent  
142 age group. Throughout the analysis we have weighted outpatient visits to be nationally  
143 representative using the sampling and nonresponse weights provided in NAMCS/NHAMCS. Let  
144  $X_{as}$  be the number of avertable exposures by antibiotic and species,  $T_{as}$  be the total number of  
145 exposures by antibiotic and species,  $d_{aig}$  be the number of prescriptions of antibiotic  $a$  associated  
146 with diagnosis code  $i$  in age group  $g$ ,  $p_{sig}$  be the carriage prevalence of species  $s$  among those  
147 with diagnosis code  $i$  in age group  $g$ , and  $q_{aig}$  be the proportion of avertable exposures by

148 diagnosis code and age group in the given scenario. For example, in the scenario assessing  
149 elimination of all unnecessary antibiotic use,  $q_{aig}$  is the proportion of avertable antibiotic use by  
150 diagnosis and age group (Fleming-Dutra et al., 2016). Alternatively, in the scenario assessing  
151 elimination of non-nitrofurantoin treatment for cystitis,  $q_{aig}$  is 1 when  $a$  is not nitrofurantoin,  $i$  is  
152 a diagnosis code associated with cystitis, and the patient is female, and 0 elsewhere. Carriage  
153 prevalences ( $p_{sig}$ ) are assumed to be constant within three age groups (under 1 year, 1-5 years,  
154 over 5 years old) (Tedijanto et al., 2018), while proportions of avertable antibiotic use ( $q_{aig}$ ) were  
155 reported for three different age groups (0-19 years, 20-64 years, 65 years old and over) (Fleming-  
156 Dutra et al., 2016).  $G$  is the smallest set of age groups that accounts for this granularity (under 1  
157 year, 1-5 years, 6-19 years, 20-64 years, 65 years old and over). For antibiotic prescriptions that  
158 occurred at visits without any ICD-9-CM diagnosis codes ( $i=0$ ), we applied the carriage  
159 prevalence among healthy individuals.

160 **Equation 1.** Proportion of avertable exposures by species and antibiotic. Equation 1 – Figure  
161 Supplement 1 includes further details on all variables.


162

$$\frac{X_{as}}{T_{as}} = \frac{\sum_{g=1}^G \sum_{i=0}^I d_{aig} \times p_{sig} \times q_{aig}}{\sum_{g=1}^G \sum_{i=0}^I d_{aig} \times p_{sig}}$$

163

164 In scenarios where unnecessary use is eliminated (1 and 2), we assume that only bystander  
165 exposures are affected. Equivalently, this presumes that perfect discrimination between bacterial  
166 and non-bacterial etiologies is possible. This results in a slight modification to the numerator of  
167 Equation 1 --  $p_{sig}$  is changed to  $p_{s0g}$  as all eliminated exposures would have occurred during  
168 asymptomatic carriage. For cases where  $e_{sig}$  is 1, we assume zero avertable exposures. In  
169 addition, we make slight modifications to  $q_{aig}$  when we estimate the proportion of bacterial cases  
170 to be larger than the proportion of necessary prescriptions (Figure 1 – Source Data File 2)  
171 (Bluestone et al., 1992; Brook, 2016; Celin et al., 1991). As a sensitivity analysis, we include the

172 proportion of avertable exposures for each bacteria-antibiotic pair under Scenario 1 if antibiotic  
 173 use was eliminated equally across both target and bystander exposures (Figure 1 – Figure  
 174 Supplement 1). All analysis was conducted in R version 3.6.1.  
 175  
 176 **Results**  
 177 Results for all four scenarios are depicted in Figure 1.



178 **Figure 1.** Heatmaps showing the estimated percentage of species exposures to each antibiotic class that could be averted if *A*: unnecessary antibiotic prescriptions across all  
 179 outpatient conditions, *B*: all antibiotic use for outpatient respiratory conditions for which  
 180 antibiotics are not indicated, *C*: all antibiotic use for acute sinusitis, or *D*: non-nitrofurantoin  
 181 treatment of cystitis in women was eliminated. Drug class results include prescriptions of all  
 182 antibiotics in that class, as identified by the Lexicon Plus® classification system. Sensitivity and  
 183 other additional analyses are shown in Figure 1 – Figure Supplements 1-4.  
 184 **Abbreviations:** *Antibiotics (y-axis):* AMX-CLAV=amoxicillin-clavulanate, MACR/LINC=macrolides/  
 185 lincosamides, TMP-SMX=sulfamethoxazole-trimethoprim; *Organisms (x-axis):* EC=*E. coli*, HI=*H. influenzae*,  
 186 KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*, SA=*S. aureus*, SAg=*S. agalactiae*, SP=*S. pneumoniae*,  
 187 SPy=*S. pyogenes*; PY=person-years  
 188  
 189  
 190

191 *Scenario 1*

192 We estimate that elimination of unnecessary antibiotic prescriptions across all outpatient  
193 conditions would prevent 6 to 48% (IQR: 17 to 31%) of antibiotic-species exposures (Figure  
194 1A). The smallest reduction is associated with *S. pyogenes* exposures to cefdinir and the largest  
195 with *H. influenzae*, *E. coli*, and *P. aeruginosa* exposures to azithromycin. If all unnecessary  
196 antibiotic use could be prevented, over 30% of exposures to amoxicillin-clavulanate, penicillin,  
197 azithromycin, clarithromycin, levofloxacin, and doxycycline across most potential pathogens of  
198 interest could be averted. Of particular interest, elimination of all unnecessary prescribing in the  
199 outpatient setting could reduce exposures of *S. pneumoniae* to penicillins and macrolides by 27%  
200 and 37%, respectively, and of *S. aureus* to penicillins and quinolones by 27% and 21%. For *E.*  
201 *coli* and *K. pneumoniae*, approximately one-quarter of exposures to cephalosporins and one-fifth  
202 of exposures to quinolones could be averted.

203

204 *Scenario 2*

205 Scenario 2, elimination of all antibiotic use for outpatient respiratory conditions where  
206 antibiotics are not indicated, is a subset of Scenario 1 and accounts for a substantial portion of  
207 avertable exposures included in the first scenario. As in Scenario 1, the results are primarily  
208 driven by drug and depend on the amount of use of that drug for the affected conditions (in this  
209 case, conditions for which antibiotics are not indicated). Pathogen characteristics affecting the  
210 proportion of avertable exposures can be better understood by looking across all species for a  
211 single drug. For example, we focus on the row for azithromycin. Based on NAMCS/NHAMCS  
212 2015, 32% of all azithromycin use is associated with the affected conditions. Since these  
213 conditions are never caused by our organisms of interest, the maximum proportion of avertable

214 exposures for any species is 32%. However, the proportion of avertable exposures is modulated  
215 by the number of azithromycin exposures that occur for treatment of other conditions – for  
216 example, a lower proportion of avertable exposures for *S. pyogenes*, *M. catarrhalis*, and *S.*  
217 *agalactiae* indicates that they have relatively frequent exposure to azithromycin during treatment  
218 of other conditions that are unaffected in this scenario, often both as a bystander and causative  
219 pathogen.

220

### 221 *Scenario 3*

222 In Scenario 3, we explore elimination of all antibiotic use for acute sinusitis. Overall, acute  
223 sinusitis accounts for just 3% of prescriptions of our included antibiotic classes, resulting in the  
224 low proportions of avertable exposures across most bacteria-antibiotic combinations. However,  
225 proportions of avertable exposures are relatively high for amoxicillin-clavulanate and  
226 clarithromycin, antibiotics for which a large proportion of their use is due to acute sinusitis (15%  
227 and 9%, respectively). In this scenario, we make the assumption that all use for acute sinusitis is  
228 unnecessary. In reality, a small number of cases are truly bacterial and antibiotics are indicated  
229 for patients with persistent, severe or worsening symptoms (Rosenfeld et al., 2015). We explore  
230 varying levels of unnecessary use based on etiological data in Figure 1 – Figure Supplement 2  
231 (Aitken & Taylor, 1998; Benninger, Holzer, & Lau, 2000; Fleming-Dutra et al., 2016; Sande &  
232 Gwaltney, 2004; Snow, Mottur-Pilson, & Hickner, 2001; Wald, Guerra, & Byers, 1991;  
233 Williams, Simel, Roberts, & Samsa, 1992).

234

235

236

237 *Scenario 4*

238 In this scenario, we consider a program to prescribe only nitrofurantoin for all cases of acute  
239 cystitis in women, replacing all other antibiotics that are currently in use. As a result of this  
240 change, we estimate that exposures of *E. coli* and *K. pneumoniae* to cephalosporins could be  
241 reduced by 16% and 17%, respectively, and exposures to quinolones could decrease by 26% and  
242 28%. Uniquely in this scenario among the ones we considered, several of our species of interest  
243 cause a large proportion of UTI cases (*E. coli*, *K. pneumoniae*, and *P. aeruginosa*). To explore  
244 the effects of being a causative pathogen on the proportion of avertable exposures, we focus on  
245 the results for ciprofloxacin. Overall, 27% of ciprofloxacin use is associated with acute cystitis in  
246 women. Organisms that are not causative pathogens of cystitis have proportions of avertable  
247 exposures close to or less than 27%, but a substantially higher proportion of exposures could be  
248 averted among causative pathogens - 33%, 36%, and 44% of ciprofloxacin exposures to *E. coli*,  
249 *K. pneumoniae*, and *P. aeruginosa*, respectively. Although *E. coli* is the most common cause of  
250 UTIs, its estimated proportion of avertable exposures in this scenario is lower than that of *P.*  
251 *aeruginosa*, likely due to the larger number of antibiotic exposures incurred by *E. coli* during  
252 asymptomatic carriage.

253

254 This scenario also allows us to observe the impact of differences in disease incidence, antibiotic  
255 use patterns, and carriage prevalence across age groups on the proportion of avertable exposures.  
256 For example, *M. catarrhalis* is asymptotically carried in children much more frequently than  
257 in adults. Since cystitis occurs primarily in adults, the proportion of avertable exposures is often  
258 lower for *M. catarrhalis* compared to other species due to bystander exposures in children that  
259 are largely unaffected by modified prescribing practices for cystitis. This age group effect can be



260 substantial for antibiotics that are commonly given to children, especially when the antibiotic is  
261 also used to treat a condition caused by *M. catarrhalis* (e.g. cefdinir and otitis media), but is less  
262 influential for antibiotics that are infrequently prescribed to children, such as ciprofloxacin and  
263 levofloxacin.

264  
265 Overall, the proportion of avertable exposures is driven by pathogen, syndrome, and prescribing  
266 characteristics. Because our organisms of interest experience the vast majority of their antibiotic  
267 exposures as bystanders, the metric is largely dependent on the proportion of antibiotic use that is  
268 associated with the conditions affected in the given scenario. In a scenario where all antibiotic  
269 use for affected conditions is eliminated, this proportion would be equal to the proportion of  
270 avertable exposures for organisms exposed to antibiotics only during carriage (never pathogens).  
271 Being a causative pathogen for any of the affected conditions increases the proportion of  
272 avertable exposures. In contrast, being a causative pathogen for unaffected conditions increases  
273 unaffected antibiotic exposures and thus decreases the proportion of avertable exposures. For  
274 pathogens responsible for multiple syndromes, both factors may be at play. Finally,  
275 asymptomatic carriage prevalence is positively associated with both affected and unaffected  
276 antibiotic exposures, and, as a result, its overall effect on the proportion of avertable exposures is  
277 dependent on the bacteria-antibiotic combination of interest.

278

## 279 **Discussion**

280 We quantify the species-level impact of changes in antibiotic consumption as the proportion of  
281 antibiotic exposures experienced by common bacterial pathogens that could be averted under  
282 four hypothetical scenarios. In the scenario where unnecessary antibiotic use for all outpatient

283 conditions is eliminated, we find that up to 48% of exposures (of *H. influenzae*, *E. coli*, and *P.*  
284 *aeruginosa* to azithromycin) could be avoided. In addition, impact of the intervention across  
285 antibiotics and species is widespread, with half of antibiotic-species pairs expected to experience  
286 a reduction in exposures of over one-fifth (22%). For conditions which require antibiotic  
287 treatment, such as UTIs, switching to antibiotics with decreased collateral damage to the  
288 microbiome, such as nitrofurantoin, may be an effective strategy for reducing antibiotic  
289 exposures across species.

290  
291 In three out of four situations we assess, antibiotics are considered entirely unnecessary for some  
292 or all cases. In the future, this method may also be extended to measure net changes in exposures  
293 resulting from more nuanced scenarios where one antibiotic is substituted for another. We did  
294 not assess such changes for nitrofurantoin, as its effects on the microbiome outside of the bladder  
295 are thought to be minimal (Stewardson et al., 2015). The reductions in use presented here may be  
296 practically infeasible due to challenges including similar clinical presentation of viral and  
297 bacterial infections, laboratory processing times that prevent identification of causative  
298 pathogens during outpatient visits, individual considerations such as allergies (Sakoulas, Geriak,  
299 & Nizet, 2018) or heightened risk of adverse events, misdiagnosis (Filice et al., 2015; Tomas,  
300 Getman, Donskey, & Hecker, 2015), and patient-driven demand (Vanden Eng et al., 2003). Even  
301 if elimination of unnecessary use were fully realized, our results imply that the majority of  
302 species' antibiotic exposures occur in the context of "necessary" antibiotic use. These findings  
303 underscore the importance of considering bystander effects and the need for a multi-pronged  
304 approach to programs aimed at controlling antibiotic resistance. Rapid diagnostics, diagnostics  
305 that accurately discriminate between bacterial and non-bacterial causes, patient education, and

306 improved decision-making tools and other interventions to motivate changes in clinician  
307 behavior can enhance responsible antibiotic consumption and reduce unnecessary antibiotic use;  
308 these should be implemented simultaneously with prevention measures such as infection control,  
309 access to clean water and sanitation, safe sex interventions, and vaccination, which aim to reduce  
310 infection incidence and thus any antibiotic use.

311  
312 At the time of this analysis, NHAMCS data from hospital outpatient departments was not  
313 available for 2015. In the 2010-2011 NAMCS/NHAMCS data, visits to hospital outpatient  
314 departments accounted for 36% of included sampled visits, but just 9% of all antibiotic mentions.  
315 Since the proportions of avertable exposures including and excluding these visits for 2010-2011  
316 were similar for Scenario 1 (Figure 1 – Figure Supplement 3), we assumed that the existing 2015  
317 data without hospital outpatient department visits was representative of the NAMCS/NHAMCS  
318 population for the purposes of our analysis. Certain outpatient encounters are also outside the  
319 scope of NAMCS/NHAMCS, including federal facility visits, telephone contacts, house calls,  
320 long-term care stays, urgent care, retail clinics, and hospital discharge prescriptions.

321  
322 Additional limitations of the included datasets and method for estimating antibiotic exposures  
323 have been previously enumerated (Tedijanto et al., 2018). Notably, the NAMCS/NHAMCS does  
324 not provide information to link medications with diagnoses, so we adopted a published tiered  
325 system to pair antibiotic use at each visit with the most likely indication (Fleming-Dutra et al.,  
326 2016). For visits with multiple diagnoses, all antibiotic use was attributed to the single most-  
327 likely indication. This method tends to overestimate antibiotic use for conditions for which  
328 antibiotics are almost always indicated, which may lead to clinically unusual diagnosis-treatment

329 linkages. In the same way, antibiotic prescriptions are underestimated for diagnoses for which  
330 antibiotic use is not indicated, potentially leading to downward bias in avertable exposures for  
331 these conditions. Additionally, NAMCS/NHAMCS antibiotic use data does not include  
332 prescription details such as duration or dose. Future studies with more granular data may extend  
333 the methods presented here to account for such factors.

334  
335 At the time of this analysis, Fleming-Dutra et al. remained the most up-to-date source of  
336 unnecessary antibiotic prescribing by condition. Recent work with slightly different methods  
337 found a lower proportion of inappropriate antibiotic prescriptions overall (23.2% compared to  
338 30%) but did not report their estimates by condition (Chua et al., 2019). Although comparable  
339 estimates of unnecessary prescribing over time are unavailable, multiple studies have shown that  
340 declines in antibiotic use from approximately 2011 to 2016 in the United States have been  
341 primarily due to pediatric prescribing, implying that, at least for adults, levels of unnecessary  
342 prescribing likely remained similar (Durkin et al., 2018; King, Bartoces, Fleming-Dutra, Roberts,  
343 & Hicks, 2019; Klevens et al., 2019; Olesen, Barnett, MacFadden, Lipsitch, et al., 2018). We  
344 also assume that the proportion of unnecessary use is constant across all antibiotic use for the  
345 same condition as it is difficult to identify specific antibiotic prescriptions that were unwarranted  
346 without detailed chart review. A study among outpatients in the Veterans Affairs medical system  
347 found that among prescriptions for community-acquired pneumonia, sinusitis, and acute  
348 exacerbations of chronic bronchitis, the highest proportion of macrolide use was inappropriate  
349 (27%), followed by penicillins (22%) and quinolones (12%) (Tobia, Aspinall, Good, Fine, &  
350 Hanlon, 2008). Similar studies are needed to understand which antibiotics are frequently used  
351 inappropriately for other indications and settings.

352 Finally, it is important to note that the reduction in antibiotic exposures estimated here does not  
353 translate to the same reduction in the prevalence of resistance or in the morbidity and mortality  
354 attributable to resistance. Although population-level antibiotic consumption has been positively  
355 correlated with levels of antibiotic resistance, the impact of changing consumption is not well-  
356 understood and is likely to vary widely by bacteria-antibiotic combination (or even strain-  
357 antibiotic combination) based on resistance mechanisms, fitness costs, and co-selection, among  
358 other factors (Andersson & Hughes, 2010; Pouwels et al., 2017). Antibiotic consumption is also  
359 highly heterogeneous and the impact of stewardship on resistance may depend on the affected  
360 patient populations (Olesen, Barnett, MacFadden, Brownstein, et al., 2018). Additionally, in this  
361 analysis, we give each exposure equal weight. However, the selective pressure imposed by a  
362 single exposure depends on a number of variables, including pharmacokinetics,  
363 pharmacodynamics, distribution of bacteria across body sites, and bacterial population size. For  
364 example, we might expect that the probability of resistance scales with population size, and thus  
365 that an exposure received by an individual with higher bacterial load will have a larger impact on  
366 resistance. Further research, integrating knowledge from clinical, ecological, and evolutionary  
367 spheres, is needed to elucidate the relationship between antibiotic use and selective pressures and  
368 ultimately between use and resistance at the population level (MacLean & San Millan, 2019).

369

370 Reductions in antibiotic consumption are necessary to preserve the potency of these drugs.  
371 Quantifying changes in species-level exposures due to stewardship programs is one more step  
372 towards understanding how changes in antibiotic use correspond to antibiotic resistance. The  
373 methods presented here may be easily extended to incorporate other data sources, such as claims,  
374 or to assess more specific stewardship programs. We show that while improved prescribing

375 practices have the potential to prevent antibiotic exposures experienced by bacterial species  
376 throughout the microbiome, complementary efforts to facilitate appropriate antibiotic  
377 consumption and decrease overall infection incidence are required to substantially avert  
378 exposures.

### 379 **Acknowledgements**

380 We thank Dr. Lauri Hicks for her helpful comments on this manuscript.

381

### 382 **Competing Interests**

383 ML has received consulting income from Affinivax, Antigen Discovery, Merck, and Pfizer and  
384 research grants through Harvard School of Public Health from Pfizer and PATH. YHG has  
385 received consulting income from Merck and GlaxoSmithKline. The authors have no other  
386 relationships or activities that could appear to have influenced the submitted work.

387

### 388 **Funding Sources**

389 This work was supported by Grant U54GM088558 (Models of Infectious Disease Agent Study,  
390 Center for Communicable Disease Dynamics) from the National Institute of General Medical  
391 Sciences, Grant R01AI132606 from the National Institute of Allergy and Infectious Diseases (to  
392 YHG), Grant CK000538-01 from the Centers for Disease Control and Prevention, and the Doris  
393 Duke Charitable Foundation. CT is supported by Grant T32AI007535 from the National Institute  
394 of Allergy and Infectious Diseases. The content is solely the responsibility of the authors and  
395 does not necessarily represent the official views of the National Institute of General Medical  
396 Sciences, National Institutes of Health, National Institute of Allergy and Infectious Diseases,  
397 Centers for Disease Control and Prevention, Department of Health and Human Services, or the  
398 Doris Duke Charitable Foundation.

399

### 400 **Figure Supplements**

401

402 *Equation 1 – Figure Supplement 1.* Notation, descriptions, and sources for variables in Equation  
403 1.

404

405 *Figure 1 – Figure Supplement 1.* Sensitivity analysis of proportions of avertable exposures  
406 across all outpatient conditions when proportion of unnecessary use is applied equally across  
407 target and bystander exposures (Equation 1 without modification).

408

409 *Figure 1 – Figure Supplement 2.* Sensitivity analyses for Scenario 3 (elimination of all antibiotic  
410 use for acute sinusitis).

411

412 *Figure 1 – Figure Supplement 3.* Proportions of avertable exposures under Scenario 1  
413 (elimination of all unnecessary antibiotic use across outpatient conditions) using 2010-2011  
414 NAMCS/NHAMCS data with and without NHAMCS outpatient department data.

415

416

417 **Source Data Files**

418

419 *Figure 1 – Source Data File 1.* Summary of etiology studies.

420

421 *Figure 1 – Source Data File 2.* Modifications to proportions of unnecessary antibiotic  
422 prescriptions based on published etiology studies and antibiotic use in NAMCS/NHAMCS.  
423 Modifications were made if the reported proportion of bacterial cases for a given condition  
424 exceeded the estimated proportion of appropriate prescriptions reported in Fleming-Dutra et al.

425

426 *Figure 1 – Source Data File 3.* Estimated antibiotic class exposures by exposed and causative  
427 species.

428

429

## 430 **References**

- 431
- 432 Aitken, M., & Taylor, J. A. (1998). Prevalence of Clinical Sinusitis in Young Children Followed Up by Primary  
433 Care Pediatricians. *Archives of Pediatrics & Adolescent Medicine*, *152*(3), 244–248.  
434 <https://doi.org/10.1001/archpedi.152.3.244>
- 435 Andersson, D. I., & Hughes, D. (2010). Antibiotic resistance and its cost: Is it possible to reverse resistance? *Nature*  
436 *Reviews Microbiology*, *8*(4), 260–271. <https://doi.org/10.1038/nrmicro2319>
- 437 Bäckhed, F., Roswall, J., Peng, Y., Feng, Q., Jia, H., Kovatcheva-Datchary, P., ... Wang, J. (2015). Dynamics and  
438 Stabilization of the Human Gut Microbiome during the First Year of Life. *Cell Host & Microbe*, *17*(5),  
439 690–703. <https://doi.org/10.1016/j.chom.2015.04.004>
- 440 Benninger, M. S., Holzer, S. E. S., & Lau, J. (2000). Diagnosis and treatment of uncomplicated acute bacterial  
441 rhinosinusitis: Summary of the Agency for Health Care Policy and Research evidence-based report.  
442 *Otolaryngology–Head and Neck Surgery*, *122*(1), 1–7. [https://doi.org/10.1016/S0194-5998\(00\)70135-5](https://doi.org/10.1016/S0194-5998(00)70135-5)
- 443 Bluestone, C. D., Stephenson, J. S., & Martin, L. M. (1992). Ten-year review of otitis media pathogens. *The*  
444 *Pediatric Infectious Disease Journal*, *11*(8), S7–S11. <https://doi.org/10.1097/00006454-199208001-00002>
- 445 Bogaert, D., Keijsers, B., Huse, S., Rossen, J., Veenhoven, R., Gils, E. V., ... Sanders, E. (2011). Variability and  
446 Diversity of Nasopharyngeal Microbiota in Children: A Metagenomic Analysis. *PLoS ONE*, *6*(2), e17035.  
447 <https://doi.org/10.1371/journal.pone.0017035>
- 448 Brook, I. (2016). Microbiology of chronic rhinosinusitis. *European Journal of Clinical Microbiology & Infectious*  
449 *Diseases*, *35*(7), 1059–1068. <https://doi.org/10.1007/s10096-016-2640-x>
- 450 Brook, I., Thompson, D. H., & Frazier, E. H. (1994). Microbiology and Management of Chronic Maxillary Sinusitis.  
451 *Archives of Otolaryngology–Head & Neck Surgery*, *120*(12), 1317–1320.
- 452 Buffie, C. G., & Pamer, E. G. (2013). Microbiota-mediated colonization resistance against intestinal pathogens.  
453 *Nature Reviews Immunology*, *13*(11), 790–801. <https://doi.org/10.1038/nri3535>
- 454 Burgstaller, J. M., Steurer, J., Holzmann, D., Geiges, G., & Soyka, M. B. (2016). Antibiotic efficacy in patients with  
455 a moderate probability of acute rhinosinusitis: A systematic review. *European Archives of Oto-Rhino-*  
456 *Laryngology*, *273*(5), 1067–1077. <https://doi.org/10.1007/s00405-015-3506-z>
- 457 Celin, S. E., Bluestone, C. D., Stephenson, J., Yilmaz, H. M., & Collins, J. J. (1991). Bacteriology of Acute Otitis  
458 Media in Adults. *JAMA*, *266*(16), 2249–2252. <https://doi.org/10.1001/jama.266.16.2249>



- 459 Chira, S., & Miller, L. G. (2010). *Staphylococcus aureus* is the most common identified cause of cellulitis: A  
460 systematic review. *Epidemiology and Infection*, *138*(3), 313–317.  
461 <https://doi.org/10.1017/S0950268809990483>
- 462 Chua, K.-P., Fischer, M. A., & Linder, J. A. (2019). Appropriateness of outpatient antibiotic prescribing among  
463 privately insured US patients: ICD-10-CM based cross sectional study. *BMJ*, *364*(k5092).  
464 <https://doi.org/10.1136/bmj.k5092>
- 465 Durkin, M. J., Jafarzadeh, S. R., Hsueh, K., Sallah, Y. H., Munshi, K. D., Henderson, R. R., & Fraser, V. J. (2018).  
466 Outpatient Antibiotic Prescription Trends in the United States: A National Cohort Study. *Infection Control*  
467 *& Hospital Epidemiology*, *39*(5), 584–589. <https://doi.org/10.1017/ice.2018.26>
- 468 Edlin, R. S., Shapiro, D. J., Hersh, A. L., & Copp, H. L. (2013). Antibiotic resistance patterns of outpatient pediatric  
469 urinary tract infections. *The Journal of Urology*, *190*(1), 222–227.  
470 <https://doi.org/10.1016/j.juro.2013.01.069>
- 471 European Centre for Disease Prevention and Control. (2018). *Antimicrobial consumption: Annual epidemiological*  
472 *report for 2017*. Stockholm.
- 473 Filice, G. A., Drekonja, D. M., Thurn, J. R., Hamann, G. M., Masoud, B. T., & Johnson, J. R. (2015). Diagnostic  
474 Errors that Lead to Inappropriate Antimicrobial Use. *Infection Control & Hospital Epidemiology*, *36*(8),  
475 949–956. <https://doi.org/10.1017/ice.2015.113>
- 476 Fleming-Dutra, K. E., Hersh, A. L., Shapiro, D. J., Bartoces, M., Enns, E. A., File, T. M., ... Hicks, L. A. (2016).  
477 Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011.  
478 *JAMA*, *315*(17), 1864–1873. <https://doi.org/10.1001/jama.2016.4151>
- 479 Fokkens, W., Lund, V., & Mullol, J. (2007). European position paper on rhinosinusitis and nasal polyps 2007. A  
480 summary for otorhinolaryngologists. *Rhinology*, *45*(97).
- 481 Ginsburg, C. M., McCracken, G. H., Crow, S. D., Dildy, B. R., Morchower, G., Steinberg, J. B., & Lancaster, K.  
482 (1985). Seroepidemiology of the Group-A Streptococcal Carriage State in a Private Pediatric Practice.  
483 *American Journal of Diseases of Children*, *139*(6), 614–617.  
484 <https://doi.org/10.1001/archpedi.1985.02140080084039>
- 485 Gunnarsson, R. K., Holm, S. E., & Söderström, M. (1997). The prevalence of beta-haemolytic streptococci in throat  
486 specimens from healthy children and adults: Implications for the clinical value of throat cultures.

- 487 *Scandinavian Journal of Primary Health Care*, 15(3), 149–155.
- 488 <https://doi.org/10.3109/02813439709018506>
- 489 Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., ... Soper, D. E. (2011). International  
490 Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in  
491 Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for  
492 Microbiology and Infectious Diseases. *Clinical Infectious Diseases*, 52(5), e103–e120.  
493 <https://doi.org/10.1093/cid/ciq257>
- 494 Gupta, K., Scholes, D., & Stamm, W. E. (1999). Increasing prevalence of antimicrobial resistance among  
495 uropathogens causing acute uncomplicated cystitis in women. *JAMA*, 281(8), 736–738.  
496 <https://doi.org/10.1001/jama.281.8.736>
- 497 Gwaltney, Jack M., Scheld, W. M., Sande, M. A., & Sydnor, A. (1992). The Microbial Etiology and Antimicrobial  
498 Therapy of Adults with Acute Community-Acquired Sinusitis—A 15-Year Experience at the University of  
499 Virginia and Review of Other Selected Studies. *Journal of Allergy and Clinical Immunology*, 90(3), 457–  
500 462. [https://doi.org/10.1016/0091-6749\(92\)90169-3](https://doi.org/10.1016/0091-6749(92)90169-3)
- 501 Hammitt, L. L., Bruden, D. L., Butler, J. C., Baggett, H. C., Hurlburt, D. A., Reasonover, A., & Hennessy, T. W.  
502 (2006). Indirect Effect of Conjugate Vaccine on Adult Carriage of *Streptococcus pneumoniae*: An  
503 Explanation of Trends in Invasive Pneumococcal Disease. *The Journal of Infectious Diseases*, 193(11),  
504 1487–1494. <https://doi.org/10.1086/503805>
- 505 Holgerson, P. L., Öhman, C., Rönnlund, A., & Johansson, I. (2015). Maturation of oral microbiota in children with  
506 or without dental caries. *PLoS ONE*, 10(5), 1–20. <https://doi.org/10.1371/journal.pone.0128534>
- 507 Hooton, T. M., & Gupta, K. (2019). Acute simple cystitis in women. In *UpToDate, Post, TW (Ed)*. Retrieved from  
508 <https://www.uptodate.com/contents/acute-simple-cystitis-in-women>
- 509 Huang, Susan S., Hinrichsen, V. L., Stevenson, A. E., Rifas-Shiman, S. L., Kleinman, K., Pelton, S. I., ...  
510 Finkelstein, J. A. (2009). Continued Impact of Pneumococcal Conjugate Vaccine on Carriage in Young  
511 Children. *Pediatrics*, 124(1), e1–e11. <https://doi.org/10.1542/peds.2008-3099>
- 512 Huttenhower, C., Gevers, D., Knight, R., Abubucker, S., Badger, J. H., Chinwalla, A. T., ... White, O. (2012).  
513 Structure, function and diversity of the healthy human microbiome. *Nature*, 486(7402), 207–214.  
514 <https://doi.org/10.1038/nature11234>

- 515 Jain, S., Self, W. H., Wunderink, R. G., Fakhran, S., Balk, R., Bramley, A. M., ... Finelli, L. (2015). Community-  
516 Acquired Pneumonia Requiring Hospitalization among U.S. Adults. *New England Journal of Medicine*,  
517 373(5), 415–427. <https://doi.org/10.1056/NEJMoa1500245>
- 518 Kabbani, S., Hersh, A. L., Shapiro, D. J., Fleming-Dutra, K. E., Pavia, A. T., & Hicks, L. A. (2018). Opportunities  
519 to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care Visits. *Clinical*  
520 *Infectious Diseases*, 67(1), 134–136. <https://doi.org/10.1093/cid/ciy035>
- 521 Khosravi, A., & Mazmanian, S. K. (2013). Disruption of the gut microbiome as a risk factor for microbial  
522 infections. *Current Opinion in Microbiology*, 16(2), 221–227. <https://doi.org/10.1016/j.mib.2013.03.009>
- 523 King, L. M., Bartoces, M., Fleming-Dutra, K. E., Roberts, R. M., & Hicks, L. A. (2019). Changes in US Outpatient  
524 Antibiotic Prescriptions from 2011-2016. *Clinical Infectious Diseases*. <https://doi.org/10.1093/cid/ciz225>
- 525 Klevens, R. M., Caten, E., Olesen, S. W., DeMaria, A., Troppy, S., & Grad, Y. H. (2019). Outpatient antibiotic  
526 prescribing in Massachusetts, 2011-2015. *Open Forum Infectious Diseases*, 6(5), ofz169.  
527 <https://doi.org/10.1093/ofid/ofz169>
- 528 *Lexicon Plus*. (2008). Retrieved from <https://www.cerner.com/solutions/drug-database>
- 529 Linder, J. A. (2008). *Editorial Commentary*: Antibiotics for Treatment of Acute Respiratory Tract Infections:  
530 Decreasing Benefit, Increasing Risk, and the Irrelevance of Antimicrobial Resistance. *Clinical Infectious*  
531 *Diseases*, 47(6), 744–746. <https://doi.org/10.1086/591149>
- 532 Lipsitch, M. (2001). The rise and fall of antimicrobial resistance. *Trends in Microbiology*, 9(9), 438–444.  
533 [https://doi.org/10.1016/S0966-842X\(01\)02130-8](https://doi.org/10.1016/S0966-842X(01)02130-8)
- 534 MacLean, R. C., & San Millan, A. (2019). The evolution of antibiotic resistance. *Science*, 365(6458), 1082–1083.  
535 <https://doi.org/10.1126/science.aax3879>
- 536 Mainous, Arch G., Hueston, W. J., Everett, C. J., & Diaz, V. A. (2006). Nasal Carriage of *Staphylococcus aureus*  
537 and Methicillin-Resistant *S aureus* in the United States, 2001-2002. *The Annals of Family Medicine*, 4(2),  
538 132–137. <https://doi.org/10.1370/afm.526>
- 539 National Center for Health Statistics. (2015a). *National Ambulatory Medical Care Survey—Public-use data file and*  
540 *documentation*. Retrieved from [ftp://ftp.cdc.gov/pub/Health\\_Statistics/NCHS/Datasets/NAMCS](ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Datasets/NAMCS)

- 541 National Center for Health Statistics. (2015b). *National Hospital Ambulatory Medical Care Survey—Public-use*  
542 *data file and documentation*. Retrieved from  
543 [ftp://ftp.cdc.gov/pub/Health\\_Statistics/NCHS/Datasets/NHAMCS](ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Datasets/NHAMCS)
- 544 Olesen, S. W., Barnett, M. L., MacFadden, D. R., Brownstein, J. S., Hernández-Díaz, S., Lipsitch, M., & Grad, Y.  
545 H. (2018). The distribution of antibiotic use and its association with antibiotic resistance. *ELife*, 7(e39435).  
546 <https://doi.org/10.7554/eLife.39435.001>
- 547 Olesen, S. W., Barnett, M. L., MacFadden, D. R., Lipsitch, M., & Grad, Y. H. (2018). Trends in outpatient antibiotic  
548 prescribing practice among US older adults, 2011-2015: An observational study. *BMJ*, 362, k3155.  
549 <https://doi.org/10.1136/bmj.k3155>
- 550 Pettigrew, M. M., Laufer, A. S., Gent, J. F., Kong, Y., Fennie, K. P., & Metlay, J. P. (2012). Upper respiratory tract  
551 microbial communities, acute otitis media pathogens, and antibiotic use in healthy and sick children.  
552 *Applied and Environmental Microbiology*, 78(17), 6262–6270. <https://doi.org/10.1128/AEM.01051-12>
- 553 Pouwels, K. B., Batra, R., Patel, A., Edgeworth, J. D., Robotham, J. V., & Smieszek, T. (2017). Will co-trimoxazole  
554 resistance rates ever go down? Resistance rates remain high despite decades of reduced co-trimoxazole  
555 consumption. *Journal of Global Antimicrobial Resistance*, 11, 71–74.  
556 <https://doi.org/10.1016/j.jgar.2017.07.013>
- 557 Public Health Agency of Canada. (2018). *Canadian Antimicrobial Resistance Surveillance System 2017 Report*.
- 558 Public Health England. (2017). *English Surveillance Programme for Antimicrobial Utilisation and Resistance*  
559 *(ESPAUR) 2017*.
- 560 Regev-Yochay, G., Dagan, R., Raz, M., Carmeli, Y., Shainberg, B., Derazne, E., ... Rubinstein, E. (2004).  
561 Association Between Carriage of *Streptococcus pneumoniae* and *Staphylococcus aureus* in Children.  
562 *JAMA*, 292(6), 716–720. <https://doi.org/10.1001/jama.292.6.716>
- 563 Rosenfeld, R. M., Piccirillo, J. F., Chandrasekhar, S. S., Brook, I., Kumar, K. A., Kramper, M., ... Corrigan, M. D.  
564 (2015). Clinical Practice Guideline (Update): Adult Sinusitis. *Otolaryngology—Head and Neck Surgery*,  
565 152(2S), S1–S39. <https://doi.org/10.1177/0194599815572097>
- 566 Sakoulas, G., Geriak, M., & Nizet, V. (2018). Is a Reported Penicillin Allergy Sufficient Grounds to Forgo the  
567 Multidimensional Antimicrobial Benefits of  $\beta$ -Lactam Antibiotics? *Clinical Infectious Diseases*, 68(1),  
568 157–164. <https://doi.org/10.1093/cid/ciy557>

- 569 Sande, M. A., & Gwaltney, J. M. (2004). Acute Community-Acquired Bacterial Sinusitis: Continuing Challenges  
570 and Current Management. *Clinical Infectious Diseases*, 39, S151–S158. <https://doi.org/10.1086/421353>
- 571 Shehab, N., Patel, P. R., Srinivasan, A., & Budnitz, D. S. (2008). Emergency Department Visits for Antibiotic-  
572 Associated Adverse Events. *Clinical Infectious Diseases*, 47(6), 735–743. <https://doi.org/10.1086/591126>
- 573 Smith, S. S., Evans, C. T., Tan, B. K., Chandra, R. K., Smith, S. B., & Kern, R. C. (2013). National burden of  
574 antibiotic use for adult rhinosinusitis. *Journal of Allergy and Clinical Immunology*, 132(5), 1230–1232.  
575 <https://doi.org/10.1016/j.jaci.2013.07.009>
- 576 Snow, V., Mottur-Pilson, C., & Hickner, J. M. (2001). Principles of Appropriate Antibiotic Use for Acute Sinusitis  
577 in Adults. *Annals of Internal Medicine*, 134(6), 495. <https://doi.org/10.7326/0003-4819-134-6-200103200-00016>
- 578
- 579 Stewardson, A. J., Gaïa, N., François, P., Malhotra-Kumar, S., Delémont, C., Martinez de Tejada, B., ... Lazarevic,  
580 V. (2015). Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract  
581 infections: A culture-free analysis of gut microbiota. *Clinical Microbiology and Infection*, 21(4), 344.e1-  
582 344.e11. <https://doi.org/10.1016/j.cmi.2014.11.016>
- 583 Swedres-Svarm. (2017). *Consumption of antibiotics and occurrence of antibiotic resistance in Sweden*. Public  
584 Health Agency of Sweden and National Veterinary Institute.
- 585 Tedijanto, C., Olesen, S. W., Grad, Y. H., & Lipsitch, M. (2018). Estimating the proportion of bystander selection  
586 for antibiotic resistance among potentially pathogenic bacterial flora. *Proceedings of the National Academy  
587 of Sciences*, 115(51), E11988–E11995. <https://doi.org/10.1073/pnas.1810840115>
- 588 The Human Microbiome Project Consortium. (2012). A framework for human microbiome research. *Nature*,  
589 486(7402), 215–221. <https://doi.org/10.1038/nature11209>
- 590 Tobia, C. C., Aspinall, S. L., Good, C. B., Fine, M. J., & Hanlon, J. T. (2008). Appropriateness of antibiotic  
591 prescribing in veterans with community-acquired pneumonia, sinusitis, or acute exacerbations of chronic  
592 bronchitis: A cross-sectional study. *Clinical Therapeutics*, 30(6), 1135–1144.  
593 <https://doi.org/10.1016/j.clinthera.2008.06.009>
- 594 Tomas, M. E., Getman, D., Donskey, C. J., & Hecker, M. T. (2015). Overdiagnosis of Urinary Tract Infection and  
595 Underdiagnosis of Sexually Transmitted Infection in Adult Women Presenting to an Emergency  
596 Department. *Journal of Clinical Microbiology*, 53(8), 2686–2692. <https://doi.org/10.1128/JCM.00670-15>

- 597 Vanden Eng, J., Marcus, R., Hadler, J. L., Imhoff, B., Vugia, D. J., Cieslak, P. R., ... Besser, R. E. (2003).  
598 Consumer Attitudes and Use of Antibiotics. *Emerging Infectious Diseases*, 9(9), 1128–1135.  
599 <https://doi.org/10.3201/eid0909.020591>
- 600 Verhaegh, S. J. C., Lebon, A., Saarloos, J. A., Verbrugh, H. A., Jaddoe, V. W. V., Hofman, A., ... van Belkum, A.  
601 (2010). Determinants of *Moraxella catarrhalis* colonization in healthy Dutch children during the first 14  
602 months of life. *Clinical Microbiology and Infection*, 16(7), 992–997. [https://doi.org/10.1111/j.1469-](https://doi.org/10.1111/j.1469-0691.2009.03008.x)  
603 [0691.2009.03008.x](https://doi.org/10.1111/j.1469-0691.2009.03008.x)
- 604 Wald, E. R., Guerra, N., & Byers, C. (1991). Upper Respiratory Tract Infections in Young Children: Duration of and  
605 Frequency of Complications. *Pediatrics*, 87(2), 129–133.
- 606 Williams, J. W., Simel, D. L., Roberts, L., & Samsa, G. P. (1992). Clinical Evaluation for Sinusitis. *Annals of*  
607 *Internal Medicine*, 117(9), 705–710. <https://doi.org/10.7326/0003-4819-117-9-705>
- 608 Wubbel, Loretta, Muniz, L., Ahmed, A., Trujillo, M., Carubelli, C., McCoig, C., ... McCracken, G. H. (1999).  
609 Etiology and treatment of community-acquired pneumonia in ambulatory children. *The Pediatric Infectious*  
610 *Disease Journal*, 18(2), 98–104.
- 611 Yassour, M., Vatanen, T., Siljander, H., Hämäläinen, A.-M., Härkönen, T., Ryhänen, S. J., ... Xavier, R. J. (2016).  
612 Natural history of the infant gut microbiome and impact of antibiotic treatments on strain-level diversity  
613 and stability. *Science Translational Medicine*, 8(343), 129–139.  
614 <https://doi.org/10.1126/scitranslmed.aad0917>
- 615  
616  
617  
618  
619  
620  
621  
622  
623  
624

625 **Equation 1 – Figure Supplement 1.** Notation, descriptions, and sources for variables  
 626 in Equation 1.  
 627

Variable	Definition	Source
$d_{aig}$	Number of prescriptions (using nationally representative weights) of antibiotic $a$ associated with ICD9-CM diagnosis code $i$ in age group $g$	NAMCS/NHAMCS 2015
$e_{sig}$	Proportion of cases of condition defined by ICD9-CM diagnosis code $i$ in age group $g$ caused by species $s$	Published etiology studies (see Figure 1 – Source Data File 1)
$p_{s0g}$	Asymptomatic carriage prevalence of species $s$ in age group $g$	Human Microbiome Project (HMP) and published carriage studies
$p_{sig}$	Carriage prevalence of species $s$ among individuals diagnosed with ICD9-CM code $i$ in age group $g$	$e_{sig} + (1 - e_{sig})p_{s0g}$
$q_{aig}$	Proportion of prescriptions of antibiotic $a$ associated with ICD9-CM diagnosis code $i$ in age group $g$ that are avertable under the given scenario	Based on article by Fleming-Dutra et al. (Fleming-Dutra et al., 2016) with adjustments as described in Figure 1 – Source Data File 2; note that in the nitrofurantoin-specific scenario, this variable is 1 for all antibiotic use for cystitis (ICD codes defined in main text) in women of all age groups, and 0 otherwise
$X_{as}$	Number of exposures of antibiotic $a$ experienced by species $s$ that are avertable under the given scenario	$\sum_{g=1}^G \sum_{i=0}^I d_{aig} \times p_{sig} \times q_{aig}$
$T_{as}$	Total number of exposures of antibiotic $a$ experienced by species $s$	$\sum_{g=1}^G \sum_{i=0}^I d_{aig} \times p_{sig}$


628

629



630 **Figure 1 – Figure Supplement 1.** Sensitivity analysis of proportions of avertable  
 631 exposures across all outpatient conditions when proportion of unnecessary use is  
 632 applied equally across target and bystander exposures (Equation 1 without  
 633 modification).  
 634

AMOXICILLIN	27	27	25	23	26	26	26	25	36	810.5
AMX-CLAV	37	37	35	30	37	36	36	35	51	415.3
PENICILLIN	29	29	29	32	29	29	30	30	44	83.6
<b>PENICILLINS</b>	29	29	27	25	29	29	29	27	40	<b>1381.7</b>
AZITHROMYCIN	49	49	48	44	48	49	48	48	51	869.9
CLINDAMYCIN	18	18	18	20	18	19	19	18	20	243.8
CLARITHROMYCIN	27	27	26	25	27	27	26	27	27	51.0
<b>MACR/LINC</b>	39	39	38	39	38	38	39	38	41	<b>1332.0</b>
CIPROFLOXACIN	13	15	13	20	10	15	15	15	15	547.2
LEVOFLOXACIN	30	32	30	33	26	32	33	32	33	285.0
MOXIFLOXACIN	17	17	17	20	17	17	17	17	16	71.4
<b>QUINOLONES</b>	19	20	18	24	15	21	21	21	20	<b>1026.8</b>
CEPHELEXIN	20	20	19	21	18	20	21	20	26	462.6
CEFdinIR	24	25	22	17	21	24	22	21	58	123.7
<b>CEPHALOSPORINS</b>	25	27	24	20	23	26	25	26	48	<b>1116.7</b>
DOXYCYCLINE	31	31	31	32	30	31	31	31	31	259.7
TETRACYCLINE	7	7	7	7	7	7	7	7	7	12.2
MINOCYCLINE	23	23	23	23	23	23	23	23	23	110.8
<b>TETRACYCLINES</b>	28	28	28	30	27	28	28	28	28	<b>383.1</b>
TMP-SMX	16	18	17	24	13	19	20	19	19	398.5
NITROFURANTOIN	12	13	12	14	10	14	14	14	14	191.8
	<b>EC</b>	<b>HI</b>	<b>KP</b>	<b>MC</b>	<b>PA</b>	<b>SA</b>	<b>SAG</b>	<b>SP</b>	<b>SPy</b>	Weighted prescription rate (per 10,000 PY)



635  
 636 **Abbreviations:** *Antibiotics (y-axis):* AMX-CLAV=amoxicillin-clavulanate, MACR/LINC=macrolides/  
 637 lincosamides, TMP-SMX=sulfamethoxazole-trimethoprim; *Organisms (x-axis):* EC=*E. coli*, HI=*H.*  
 638 *influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*, SA=*S. aureus*, SAG=*S.*  
 639 *agalactiae*, SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years  
 640  
 641  
 642



643 **Figure 1 – Figure Supplement 2. Sensitivity analyses for Scenario 3 (elimination of all**  
 644 **antibiotic use for acute sinusitis).**

645 **A. Use estimates of unnecessary prescribing for acute sinusitis from Fleming-Dutra et al.** Based on  
 646 Fleming-Dutra et al. (Fleming-Dutra et al., 2016), we estimate that the proportion of unnecessary  
 647 antibiotic prescriptions for acute sinusitis is 18%, 100%, and 34% for individuals who are 0-19, 20-64, and  
 648 over 65 years old, respectively (see Figure 1 – Source Data File 2).

AMOXICILLIN	1	1	1	1	1	1	1	1	1	30.6
AMX-CLAV	9	9	7	2	9	8	6	7	4	62.4
PENICILLIN										0.0
<b>PENICILLINS</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>1</b>	<b>3</b>	<b>3</b>	<b>2</b>	<b>3</b>	<b>1</b>	<b>93.2</b>
AZITHROMYCIN	4	4	4	2	4	4	3	4	3	44.9
CLINDAMYCIN										0.0
CLARITHROMYCIN	8	8	7	3	9	8	7	8	9	4.4
<b>MACR/LINC</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>1</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>51.1</b>
CIPROFLOXACIN	1	1	1	1	1	1	1	1	1	6.8
LEVOFLOXACIN	3	3	3	3	3	3	3	3	3	12.2
MOXIFLOXACIN	1	1	1	0.2	1	1	0.5	1	1	0.4
<b>QUINOLONES</b>	<b>1</b>	<b>2</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>19.6</b>
CEPHALEXIN	0.2	0.2	0.3	1	0.1	0.2	0.4	0.4	0.1	4.2
CEFDINIR	1	1	1	1	1	1	1	1	0.2	4.9
<b>CEPHALOSPORINS</b>	<b>0.3</b>	<b>0.3</b>	<b>0.3</b>	<b>1</b>	<b>0.2</b>	<b>0.3</b>	<b>0.4</b>	<b>0.4</b>	<b>0.1</b>	<b>11.1</b>
DOXYCYCLINE	4	4	4	3	4	4	3	4	3	9.8
TETRACYCLINE										0.0
MINOCYCLINE										0.0
<b>TETRACYCLINES</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>9.8</b>
TMP-SMX	1	1	1	0.3	1	1	1	1	1	3.7
NITROFURANTOIN	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.4
	<b>EC</b>	<b>HI</b>	<b>KP</b>	<b>MC</b>	<b>PA</b>	<b>SA</b>	<b>SAG</b>	<b>SP</b>	<b>SPy</b>	Weighted prescription rate (per 10,000 PY)

649

650 **B. Use estimates of bacterial etiology to approximate necessary antibiotic use for acute sinusitis.**

651 The following upper bound estimates for the proportion of acute sinusitis cases with bacterial etiology  
 652 were used: 2% for adults and 13% for children (applied to 0-19 year old age group) (Sande & Gwaltney,  
 653 2004; Snow et al., 2001; Wald et al., 1991).

AMOXICILLIN	3	3	3	2	3	3	3	3	1	30.6
AMX-CLAV	13	13	12	4	14	12	10	12	6	62.4
PENICILLIN										0.0
<b>PENICILLINS</b>	<b>6</b>	<b>6</b>	<b>5</b>	<b>3</b>	<b>6</b>	<b>5</b>	<b>4</b>	<b>5</b>	<b>3</b>	<b>93.2</b>
AZITHROMYCIN	5	5	4	2	5	4	4	4	4	44.9
CLINDAMYCIN										0.0
CLARITHROMYCIN	8	8	7	3	9	8	7	8	8	4.4
<b>MACR/LINC</b>	<b>4</b>	<b>4</b>	<b>3</b>	<b>2</b>	<b>4</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>51.1</b>
CIPROFLOXACIN	1	1	1	1	1	1	1	1	1	6.8
LEVOFLOXACIN	4	4	4	4	3	4	4	4	4	12.2
MOXIFLOXACIN	1	1	1	0.2	1	1	0.4	1	1	0.4
<b>QUINOLONES</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>19.6</b>
CEPHALEXIN	1	1	1	7	1	1	2	2	1	4.2
CEFDINIR	4	4	3	4	2	3	4	4	1	4.9
<b>CEPHALOSPORINS</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>4</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>1</b>	<b>0.4</b>	<b>11.1</b>
DOXYCYCLINE	4	4	4	4	4	4	4	4	3	9.8
TETRACYCLINE										0.0
MINOCYCLINE										0.0
<b>TETRACYCLINES</b>	<b>2</b>	<b>3</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>3</b>	<b>2</b>	<b>9.8</b>
TMP-SMX	1	1	1	0.3	1	1	1	1	1	3.7
NITROFURANTOIN	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.4
	<b>EC</b>	<b>HI</b>	<b>KP</b>	<b>MC</b>	<b>PA</b>	<b>SA</b>	<b>SAG</b>	<b>SP</b>	<b>SPy</b>	Weighted prescription rate (per 10,000 PY)

654

655 **C. Use estimates of bacterial etiology among those presenting to primary care clinics to**  
 656 **approximate necessary antibiotic use.** Patients visiting the clinic are likely to have more persistent,  
 657 severe, or worsening symptoms, which may be indications of bacterial etiology. Studies have estimated  
 658 that approximately 38% of adults and 17% of children (upper bounds) visiting primary care for symptoms  
 659 of acute upper respiratory tract infection have bacterial rhinosinusitis (Aitken & Taylor, 1998; Benninger et  
 660 al., 2000; Williams et al., 1992).

AMOXICILLIN	3	3	2	2	3	3	2	3	1	30.6
AMX-CLAV	10	10	9	4	11	9	7	9	5	62.4
PENICILLIN										0.0
<b>PENICILLINS</b>	<b>5</b>	<b>5</b>	<b>4</b>	<b>2</b>	<b>5</b>	<b>4</b>	<b>4</b>	<b>4</b>	<b>2</b>	<b>93.2</b>
AZITHROMYCIN	3	3	3	2	3	3	3	3	2	44.9
CLINDAMYCIN										0.0
CLARITHROMYCIN	5	5	4	2	5	5	5	5	5	4.4
<b>MACR/LINC</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>51.1</b>
CIPROFLOXACIN	1	1	1	1	1	1	1	1	1	6.8
LEVOFLOXACIN	2	3	2	2	2	3	3	3	3	12.2
MOXIFLOXACIN	0.3	0.4	0.3	0.1	0.4	0.3	0.3	0.3	0.3	0.4
<b>QUINOLONES</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>19.6</b>
CEPHALEXIN	1	1	1	6	0.5	1	2	2	0.5	4.2
CEFDINIR	3	3	3	4	2	3	4	4	1	4.9
<b>CEPHALOSPORINS</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>4</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>0.3</b>	<b>11.1</b>
DOXYCYCLINE	2	2	2	2	2	2	2	2	2	9.8
TETRACYCLINE										0.0
MINOCYCLINE										0.0
<b>TETRACYCLINES</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>9.8</b>
TMP-SMX	1	1	0.4	0.2	0.4	0.5	0.4	0.5	0.5	3.7
NITROFURANTOIN	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.4
	<b>EC</b>	<b>HI</b>	<b>KP</b>	<b>MC</b>	<b>PA</b>	<b>SA</b>	<b>SAG</b>	<b>SP</b>	<b>SPy</b>	Weighted prescription rate (per 10,000 PY)

661



662


663

664 **Abbreviations:** *Antibiotics (y-axis):* AMX-CLAV=amoxicillin-clavulanate, MACR/LINC=macrolides/  
 665 lincosamides, TMP-SMX=sulfamethoxazole-trimethoprim; *Organisms (x-axis):* EC=*E. coli*, HI=*H.*  
 666 *influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*, SA=*S. aureus*, SAG=*S.*  
 667 *agalactiae*, SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years

668

669

670 **Figure 1 – Figure Supplement 3.** Proportions of avertable exposures under Scenario 1  
 671 (elimination of all unnecessary antibiotic use across outpatient conditions) using 2010-  
 672 2011 NAMCS/NHAMCS data with (left) and without (right) NHAMCS outpatient  
 673 department data.



674

675 **Abbreviations:** Antibiotics (y-axis): AMX-CLAV=amoxicillin-clavulanate, MACR/LINC=macrolides/  
 676 lincosamides, TMP-SMX=sulfamethoxazole-trimethoprim; Organisms (x-axis): EC=*E. coli*, HI=*H.*  
 677 *influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*, SA=*S. aureus*, SAG=*S.*  
 678 *agalactiae*, SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years  
 679

680 **Figure 1 – Source Data File 1.** Summary of etiology studies.  
681

Publication	Study description	Etiology results
Bacteriology of Acute Otitis Media in Adults (Celin et al., 1991)	34 outpatients aged 18 years or older presenting at the emergency department and diagnosed with acute otitis media; middle-ear aspirates were collected for culture	<i>H. influenzae</i> : 26% <i>M. catarrhalis</i> : 3% <i>S. aureus</i> : 3% <i>S. pneumoniae</i> : 21% <i>S. pyogenes</i> : 3%
Ten-year review of otitis media pathogens (Bluestone et al., 1992)	2807 effusions from children with acute otitis media were collected	<i>H. influenzae</i> : 23% <i>M. catarrhalis</i> : 14% <i>S. aureus</i> : 1% <i>P. aeruginosa</i> : 1% <i>S. pneumoniae</i> : 35% <i>S. pyogenes</i> : 3%
The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: A fifteen-year experience at the University of Virginia and review of other selected studies (Gwaltney et al., 1992)	339 adult patients with acute community-acquired sinusitis; sinus aspirates were collected prior to treatment	To estimate the proportion of acute sinusitis cases caused by each organism, we multiplied the proportion of bacterial cultures in which each organism was identified (shown below) by the proportion of all acute sinusitis cases estimated to be bacterial in nature (2%) (Fokkens et al., 2007):  <i>H. influenzae</i> : 35% <i>M. catarrhalis</i> : 4% <i>S. aureus</i> : 3% <i>S. pneumoniae</i> : 41%
Microbiology and Management of Chronic Maxillary Sinusitis (Brook et al., 1994)	68 patients aged 18 to 67 years who underwent the Caldwell-Luc procedure for chronic sinusitis and whose cultures showed bacterial growth; specimens were taken from the infected sinus during surgery	<i>E. coli</i> : 2.9% <i>H. influenzae</i> : 4.4% <i>K. pneumoniae</i> : 2.9% <i>M. catarrhalis</i> : 11.8% <i>S. aureus</i> : 11.8% <i>S. agalactiae</i> : 5.9% <i>S. pneumoniae</i> : 5.9% <i>S. pyogenes</i> : 7.4%
Increasing Prevalence of Antimicrobial Resistance Among Uropathogens Causing Acute Uncomplicated Cystitis in Women (Gupta et al., 1999)	4802 women aged 18 to 50 years with an outpatient diagnosis of acute cystitis; urine samples were collected	<u>Female</u> <i>E. coli</i> : 86% <i>Klebsiella</i> spp.: 3%
Etiology and treatment of community-acquired pneumonia in ambulatory children (Wubbel et al., 1999)	174 ambulatory patients age 6 months to 16 years with radiographic and clinical evidence of pneumonia; blood, nasopharyngeal, and pharyngeal samples were collected	<i>S. pneumoniae</i> : 27%

<p><i>Staphylococcus aureus</i> is the most common identified cause of cellulitis: a systematic review (Chira &amp; Miller, 2010)</p>	<p>808 patients with cellulitis who were included in 16 studies published between 1966 and 2006; studies were eligible for inclusion if they used needle aspiration and/or punch biopsy and excluded if they pertained to ocular, odontogenic, pelvic, or surgical site-associated cellulitis</p>	<p><i>E. coli</i>: 0.4%  <i>H. influenzae</i>: 0.1%  <i>P. aeruginosa</i>: 0.5%  <i>S. aureus</i>: 8%  <i>S. agalactiae</i>: 0.5%  <i>S. pyogenes</i>: 4.3%</p>
<p>Antibiotic Resistance Patterns of Outpatient Pediatric Urinary Tract Infections (Edlin et al., 2013)</p>	<p>25,418 urinary isolates from patients younger than 18 years in the outpatient setting from 195 United States hospitals in The Surveillance Network</p>	<p><u>Female</u>  <i>E. coli</i>: 83%  <i>Klebsiella</i> spp.: 4%  <i>P. aeruginosa</i>: 2%</p> <p><u>Male</u>  <i>E. coli</i>: 50%  <i>Klebsiella</i> spp.: 10%  <i>P. aeruginosa</i>: 7%</p>
<p>Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults (Jain et al., 2015)</p>	<p>2259 patients who were hospitalized for community-acquired pneumonia (based on radiographic evidence) and had specimens for both bacterial and viral testing; specimens may have been taken from blood, acute-phase serum, urine, nasopharynx, oropharynx, sputum, pleural fluid, endotracheal aspirate, or broncho-alveolar-lavage samples</p>	<p><i>H. influenzae</i>: 0.6%  <i>Pseudomonas</i> spp.: 0.4%  <i>S. aureus</i>: 1.6%  <i>S. pneumoniae</i>: 5.1%  <i>S. pyogenes</i>: 0.3%</p>

683 **Figure 1 – Source Data File 2.** Modifications to proportions of unnecessary antibiotic  
 684 prescriptions based on published etiology studies and antibiotic use in  
 685 NAMCS/NHAMCS. Modifications were made if the estimated proportion of bacterial  
 686 cases for a given condition exceeded the estimated proportion of appropriate  
 687 prescriptions reported in Fleming-Dutra et al. (Fleming-Dutra et al., 2016).  
 688

Age group	Fleming-Dutra estimate	New estimate	Explanation
<b>Pharyngitis</b>			
0-19 years old	34%	Pharyngitis: 47%; Strep throat: 0%	Assuming that all strep-associated use of our antibiotics of interest (based on NAMCS/NHAMCS) was necessary, we estimated the proportion of non-strep pharyngitis antibiotic use that would have to be eliminated to maintain the overall estimate reported by Fleming-Dutra et al. (Fleming-Dutra et al., 2016).
20-64 years old	75%	Updated to 51% overall; Pharyngitis: 100%; Strep throat: 0%	
>64 years old	NA (assume 0%)	NA (assume 0%)	No change.
<b>Sinusitis</b>			
0-19 years old	9%	Acute: 18%; Chronic: 0%	While acute sinusitis is rarely bacterial, bacteria are believed to play a much more prominent role in the etiology of chronic sinusitis (Brook, 2016). Thus, we assume that antibiotic use would only be eliminated from acute sinusitis and maintain the overall estimate of unnecessary use reported by Fleming-Dutra et al. (Fleming-Dutra et al., 2016) when possible.
20-64 years old	51%	Updated to 40% overall; Acute: 100%; Chronic: 0%	
>64 years old	16%	Acute: 34%; Chronic: 0%	
<b>Suppurative otitis media</b>			
0-19 years old	10%	10%	No change. Approximately 84% of pediatric cases were found to have bacterial growth (Bluestone et al., 1992), so 10% is a reasonable estimate for avertable use.
20-64 years old	33%	26%	Based on an etiology study in adults, only 26% of cases were found to have no bacterial growth (Celin et al., 1991).
>64 years old	NA (assume 0%)	NA (assume 0%)	No change.

689 **Figure 1 – Source Data File 3.** Estimated antibiotic class exposures by exposed and  
690 causative species.

691  
692 The following tables contain the estimated number of annual antibiotic exposures (in 100,000s) in the  
693 outpatient setting in the United States by the species being exposed (y-axis) and the species that is the  
694 cause of antibiotic use (x-axis). The values in each table, excluding the “Other” and “Overall” columns  
695 were calculated using the following expression:  
696

697

$$\sum_{g=1}^G \sum_{i=0}^I d_{aig} \times e_{s_c i g} \times p_{s_e 0 g}$$

698  
699 Let  $a$  represent antibiotic class,  $s_c$  represent causative species,  $s_e$  represent exposed species,  $i$  represent  
700 ICD-9-CM diagnosis code, and  $g$  represent age group (under 1 year, 1-5 years, 6-19 years, 20-64 years,  
701 65 years old and over). Then,  $d_{aig}$  is the number of prescriptions of antibiotic class  $a$  associated with  
702 diagnosis code  $i$  in age group  $g$ ,  $e_{s_c i g}$  is the proportion of cases with diagnosis code  $i$  that are estimated to  
703 be caused by causative species  $s_c$  in age group  $g$ , and  $p_{s_e 0 g}$  is the healthy carriage prevalence of  
704 exposed species  $s_e$  among individuals in age group  $g$ . When  $s_c$  and  $s_e$  are the same organism,  $p_{s_e 0 g}$  is set  
705 to 1. For each variable, we use the same data sources and estimation methods described in the main text  
706 (NAMCS/NHAMCS 2015, Human Microbiome Project, and published literature).  
707

708 The diagonals, shaded in light gray, are “target” antibiotic exposures for the pathogen of interest; in other  
709 words, these are antibiotic exposures that the organism experienced because it was causing disease.  
710 The “Overall” column is all exposures to the antibiotic class of interest experienced by each species and  
711 is equivalent to  $T_{as}$  in Equation 1 of the main text. The “Other” column is the difference between the  
712 “Overall” column and the sum of the remaining columns. Note that this column represents exposures due  
713 to non-bacterial causes as well as bacterial organisms other than our nine potential pathogens of interest.  
714

715 The “Any antibiotic” table includes all prescriptions for drugs classified as antibiotics based on the Lexicon  
716 Plus® Therapeutic Classification Scheme (*Lexicon Plus*, 2008). Any drug with a Level 1 description of  
717 “anti-infectives”, but with a Level 2 description that was not “amebicides”, “anthelmintics”, “antifungals”,  
718 “antimalarial agents”, or “antiviral agents” was included as an antibiotic. The “Any included antibiotic  
719 class” table includes all prescriptions for drugs in the classes shown in the following tables. Antibiotic  
720 classes were defined using the Level 2 categories in Lexicon Plus®.  
721

722 These tables are designed to facilitate a better understanding of the “nuts and bolts” of this work and to  
723 enable calculation of other metrics of interest. For example, the proportion of bystander exposures as  
724 calculated by the authors in an earlier paper (Tedijanto et al., 2018) for any given antibiotic and species  
725 pair can be calculated as one minus the target exposures (diagonal value) over the “Overall” value. These  
726 tables can also be used to understand how interventions focused on a single species (e.g. vaccines) may  
727 reduce antibiotic exposures experienced by another species.  
728

729  
730



### Any antibiotic

Exposed species	Causative species										Overall
	E. coli	H. influenzae	K. pneumoniae	M. catarrhalis	P. aeruginosa	S. aureus	S. agalactiae	S. pneumoniae	S. pyogenes	Other	
E. coli	150.2	25.1	7.7	15.9	4.2	12.5	3.6	34.5	43.5	1838.4	2135.6
H. influenzae	103.9	31	7.9	16	4.4	12.9	3.7	34.4	44.3	1892.7	2151.2
K. pneumoniae	11.5	4.2	11.4	2.7	0.5	1.5	0.4	6.2	5.4	220.8	264.7
M. catarrhalis	4.9	7.3	0.4	19.6	0.5	1.1	0.3	12.2	6	139	191.3
P. aeruginosa	2.8	0.5	0.2	0.3	6.1	0.3	0.1	0.6	1.1	50.3	62.4
S. aureus	18.8	5.3	1.4	3.4	0.8	18.2	0.7	7.5	8.2	349.4	413.9
S. agalactiae	4.2	1.6	0.3	1	0.2	0.6	5.2	2.4	2.1	80.6	98.2
S. pneumoniae	39.2	13.3	3	8.5	1.8	5.1	1.4	40.3	19.1	743.6	875.4
S. pyogenes	7.1	1.3	0.5	0.8	0.3	0.8	0.2	1.6	60.8	125.3	198.8

731  
732

### Any included antibiotic class

Exposed species	Causative species										Overall
	E. coli	H. influenzae	K. pneumoniae	M. catarrhalis	P. aeruginosa	S. aureus	S. agalactiae	S. pneumoniae	S. pyogenes	Other	
E. coli	143.3	23.8	7.3	15	4	11.6	3.3	32.8	42.9	1042.9	1327
H. influenzae	99.2	29.5	7.6	15.1	4.1	11.9	3.4	32.8	43.7	1072.1	1319.4
K. pneumoniae	11	4	10.9	2.5	0.5	1.4	0.4	6	5.3	126.1	168.1
M. catarrhalis	4.7	6.9	0.4	18.5	0.4	1	0.3	11.6	5.9	88.8	138.5
P. aeruginosa	2.7	0.5	0.2	0.3	5.8	0.3	0.1	0.6	1.1	28.2	39.8
S. aureus	18	5.1	1.4	3.2	0.8	16.9	0.6	7.2	8.1	198.3	259.5
S. agalactiae	4	1.5	0.3	1	0.2	0.5	4.9	2.3	2.1	46.6	63.3
S. pneumoniae	37.4	12.6	2.9	8	1.7	4.8	1.4	38.4	18.8	427.4	553.4
S. pyogenes	6.7	1.2	0.5	0.8	0.3	0.8	0.2	1.5	59.9	70.5	142.5

733  
734

### Penicillins

Exposed species	Causative species										Overall
	E. coli	H. influenzae	K. pneumoniae	M. catarrhalis	P. aeruginosa	S. aureus	S. agalactiae	S. pneumoniae	S. pyogenes	Other	
E. coli	2.7	13.7	0.8	8.5	0.4	3.9	1.4	18.9	23.6	247.9	321.7
H. influenzae	2	16.3	0.8	8.5	0.4	3.9	1.4	18.8	23.8	253.1	329.1
K. pneumoniae	0.3	2.5	1.1	1.5	0.1	0.5	0.2	3.7	3.1	32	44.9
M. catarrhalis	0.3	4.6	0.1	9.9	0.2	0.6	0.2	7.4	4.6	34.3	62.2
P. aeruginosa	<0.1	0.3	<0.1	0.2	0.5	0.1	<0.1	0.3	0.6	6.3	8.3
S. aureus	0.4	3	0.1	1.9	0.1	5.3	0.3	4.3	4.5	47.9	67.8
S. agalactiae	0.1	0.9	<0.1	0.6	<0.1	0.2	2	1.4	1.3	12.3	18.8
S. pneumoniae	0.9	7.7	0.3	4.8	0.3	1.7	0.6	21.3	11.1	109.1	157.9
S. pyogenes	0.1	0.7	<0.1	0.4	<0.1	0.2	0.1	0.8	31.5	15.9	49.8

735



### Macrolides/lincosamides

Exposed species	Causative species										Overall
	E. coli	H. influenzae	K. pneumoniae	M. catarrhalis	P. aeruginosa	S. aureus	S. agalactiae	S. pneumoniae	S. pyogenes	Other	
E. coli	3.3	4.1	0.6	3	0.2	3	1	5.7	3.9	264.9	289.7
H. influenzae	2.3	5.6	0.6	3	0.2	3.1	1.1	5.8	4	272.8	298.4
K. pneumoniae	0.2	0.6	0.9	0.4	<0.1	0.4	0.1	1	0.5	31.8	36
M. catarrhalis	0.1	0.7	<0.1	4.1	<0.1	0.2	<0.1	1.4	0.4	19.6	26.6
P. aeruginosa	0.1	0.1	<0.1	0.1	0.2	0.1	<0.1	0.1	0.1	7.3	8.1
S. aureus	0.4	0.9	0.1	0.6	<0.1	4.5	0.2	1.2	0.7	50.4	59.1
S. agalactiae	0.1	0.2	<0.1	0.2	<0.1	0.1	1.5	0.3	0.2	11.6	14.3
S. pneumoniae	0.8	1.9	0.2	1.3	0.1	1.2	0.4	7.3	1.6	106.9	121.8
S. pyogenes	0.2	0.2	<0.1	0.2	<0.1	0.2	0.1	0.3	5.6	18.1	24.9

736  
737

### Quinolones

Exposed species	Causative species										Overall
	E. coli	H. influenzae	K. pneumoniae	M. catarrhalis	P. aeruginosa	S. aureus	S. agalactiae	S. pneumoniae	S. pyogenes	Other	
E. coli	61.3	0.7	2.6	0.5	1.4	0.5	0.2	1	0.3	168.7	237.2
H. influenzae	42.1	1	2.7	0.5	1.5	0.5	0.2	1	0.3	174.3	224.1
K. pneumoniae	4.5	0.1	3.9	0.1	0.2	0.1	<0.1	0.1	<0.1	19.1	28.1
M. catarrhalis	1.4	0.1	0.1	0.7	0.1	<0.1	<0.1	0.2	<0.1	7.2	9.8
P. aeruginosa	1.2	<0.1	0.1	<0.1	2.1	<0.1	<0.1	<0.1	<0.1	4.8	8.2
S. aureus	7.6	0.1	0.5	0.1	0.3	0.8	<0.1	0.2	0.1	31.5	41.1
S. agalactiae	1.6	<0.1	0.1	<0.1	0.1	<0.1	0.3	<0.1	<0.1	6.9	9.1
S. pneumoniae	15.5	0.3	1	0.2	0.5	0.2	0.1	1.3	0.1	65	84.3
S. pyogenes	2.9	<0.1	0.2	<0.1	0.1	<0.1	<0.1	0.1	0.5	11.9	15.8

738  
739

### Cephalosporins

Exposed species	Causative species										Overall
	E. coli	H. influenzae	K. pneumoniae	M. catarrhalis	P. aeruginosa	S. aureus	S. agalactiae	S. pneumoniae	S. pyogenes	Other	
E. coli	38.3	4.6	1.7	2.4	1.1	2.4	0.4	6.6	14	185.7	257.3
H. influenzae	26.8	5.6	1.8	2.4	1.1	2.5	0.4	6.5	14.5	190.8	252.3
K. pneumoniae	3	0.7	2.5	0.4	0.1	0.3	<0.1	1.1	1.6	21.9	31.9
M. catarrhalis	1.8	1.4	0.1	2.8	0.1	0.2	<0.1	2.5	0.9	15.7	25.6
P. aeruginosa	0.7	0.1	<0.1	<0.1	1.6	0.1	<0.1	0.1	0.4	5	8.1
S. aureus	4.9	0.9	0.3	0.5	0.2	3.6	0.1	1.4	2.6	35	49.5
S. agalactiae	1.1	0.3	0.1	0.2	0.1	0.1	0.6	0.5	0.6	8.3	11.7
S. pneumoniae	10.4	2.5	0.7	1.4	0.5	1	0.1	7.5	5.6	76	105.5
S. pyogenes	1.8	0.2	0.1	0.1	0.1	0.2	<0.1	0.3	20.7	12.6	36.2

740

### Tetracyclines

Exposed species	Causative species										Overall
	E. coli	H. influenzae	K. pneumoniae	M. catarrhalis	P. aeruginosa	S. aureus	S. agalactiae	S. pneumoniae	S. pyogenes	Other	
E. coli	0.7	0.3	0.1	0.1	<0.1	0.3	0.1	0.3	0.2	78.6	80.6
H. influenzae	0.5	0.4	0.1	0.1	<0.1	0.3	0.1	0.3	0.2	81.3	83.3
K. pneumoniae	0.1	<0.1	0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	8.8	9.1
M. catarrhalis	<0.1	<0.1	<0.1	0.2	<0.1	<0.1	<0.1	<0.1	<0.1	2.8	3
P. aeruginosa	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	2.2	2.3
S. aureus	0.1	0.1	<0.1	<0.1	<0.1	0.5	<0.1	<0.1	<0.1	14.6	15.4
S. agalactiae	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	0.1	<0.1	<0.1	3.2	3.3
S. pneumoniae	0.2	0.1	<0.1	<0.1	<0.1	0.1	<0.1	0.4	0.1	29.9	30.9
S. pyogenes	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	0.3	5.6	6

741  
742

### Sulfamethoxazole-trimethoprim

Exposed species	Causative species										Overall
	E. coli	H. influenzae	K. pneumoniae	M. catarrhalis	P. aeruginosa	S. aureus	S. agalactiae	S. pneumoniae	S. pyogenes	Other	
E. coli	23.1	0.3	1.1	0.5	0.6	1.5	0.3	0.4	0.8	67	95.5
H. influenzae	16.1	0.5	1.1	0.5	0.6	1.5	0.3	0.4	0.9	68.8	90.5
K. pneumoniae	1.8	<0.1	1.6	0.1	0.1	0.2	<0.1	<0.1	0.1	9	12.9
M. catarrhalis	0.9	<0.1	0.1	0.7	<0.1	0.1	<0.1	<0.1	<0.1	8.1	10
P. aeruginosa	0.4	<0.1	<0.1	<0.1	0.9	<0.1	<0.1	<0.1	<0.1	1.7	3.2
S. aureus	2.9	0.1	0.2	0.1	0.1	2.2	0.1	0.1	0.2	13.3	19.1
S. agalactiae	0.7	<0.1	<0.1	<0.1	<0.1	0.1	0.4	<0.1	<0.1	3.2	4.5
S. pneumoniae	6.1	0.1	0.4	0.2	0.2	0.6	0.1	0.6	0.3	29	37.6
S. pyogenes	1.1	<0.1	0.1	<0.1	<0.1	0.1	<0.1	<0.1	1.2	4.3	6.9

743  
744

### Nitrofurantoin

Exposed species	Causative species										Overall
	E. coli	H. influenzae	K. pneumoniae	M. catarrhalis	P. aeruginosa	S. aureus	S. agalactiae	S. pneumoniae	S. pyogenes	Other	
E. coli	13.8	<0.1	0.6	<0.1	0.3	<0.1	<0.1	<0.1	<0.1	30.1	44.9
H. influenzae	9.5	<0.1	0.6	<0.1	0.3	<0.1	<0.1	<0.1	<0.1	31.2	41.6
K. pneumoniae	1	<0.1	0.9	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	3.4	5.3
M. catarrhalis	0.3	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	1.1	1.4
P. aeruginosa	0.3	<0.1	<0.1	<0.1	0.5	<0.1	<0.1	<0.1	<0.1	0.9	1.6
S. aureus	1.7	<0.1	0.1	<0.1	0.1	<0.1	<0.1	<0.1	<0.1	5.6	7.5
S. agalactiae	0.4	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	1.2	1.6
S. pneumoniae	3.5	<0.1	0.2	<0.1	0.1	<0.1	<0.1	<0.1	<0.1	11.5	15.4
S. pyogenes	0.7	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	2.1	2.9

745  
746